|
시장보고서
상품코드
1977712
미생물 API 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)Global Microbial API Market Size, Share, Trends & Growth Analysis Report 2026-2034 |
||||||
미생물 유래 원료의약품(API) 시장 규모는 2025년 642억 3,000만 달러에서 2026년부터 2034년까지 CAGR 6.96%로 성장하여 2034년에는 1,176억 9,000만 달러에 달할 것으로 예측됩니다.
미생물 유래 원료의약품(API)에 대한 수요 증가로 세계 미생물 API 시장은 꾸준히 성장하고 있습니다. 미생물 API는 항생제, 항진균제, 기타 치료제에 널리 사용되고 있습니다. 감염병 확산과 의약품 생산 확대가 시장 성장을 뒷받침하고 있습니다. 발효 공정의 기술 발전으로 생산 효율이 향상되었습니다.
주요 성장 요인으로는 제네릭 의약품에 대한 수요 증가와 바이오의약품 제조 확대 등을 꼽을 수 있습니다. 기업들은 수율과 품질 향상을 위해 첨단 바이오 공정 기술에 대한 투자를 진행하고 있습니다. 미생물 생명공학 분야의 연구 확대도 혁신에 기여하고 있습니다. 또한, 신흥국의 의료비 지출 증가는 API 수요를 촉진하고 있습니다.
앞으로의 전망은 개선된 발효 기술과 지속가능한 생산 방식이 시장에 혜택을 가져다 줄 것으로 예상됩니다. 확장되는 세계 제약 파이프라인은 더 많은 기회를 창출할 것입니다. 제조업체는 엄격한 규제 기준을 준수하는 데 주력하고 있습니다. 전 세계 의약품 수요 증가가 지속되는 가운데, 세계 미생물 유래 API 시장은 꾸준한 성장이 예상됩니다.
목차
제1장 소개
제2장 주요 요약
제3장 시장 변수, 동향, 프레임워크
제4장 세계의 미생물 API 시장 : 호스트별
제5장 세계의 미생물 API 시장 : 유형별
제6장 세계의 미생물 API 시장 : 사이트별
제7장 세계의 미생물 API 시장 : 최종사용자별
제8장 세계의 미생물 API 시장 : 지역별
제9장 경쟁 구도
제10장 기업 개요
KSM 26.04.06The Microbial API Market size is expected to reach USD 117.69 Billion in 2034 from USD 64.23 Billion (2025) growing at a CAGR of 6.96% during 2026-2034.
The Global Microbial API Market is growing steadily due to increasing demand for active pharmaceutical ingredients derived from microbial fermentation. Microbial APIs are widely used in antibiotics, antifungals, and other therapeutic drugs. Rising prevalence of infectious diseases and expanding pharmaceutical production are supporting market growth. Technological advancements in fermentation processes are enhancing production efficiency.
Key growth drivers include increasing demand for generic drugs and expansion of biopharmaceutical manufacturing. Companies are investing in advanced bioprocessing technologies to improve yield and quality. Growing research in microbial biotechnology is also contributing to innovation. Additionally, rising healthcare expenditure in emerging economies is strengthening API demand.
Looking ahead, the market is expected to benefit from improved fermentation techniques and sustainable production practices. Expanding global drug pipelines will create additional opportunities. Manufacturers are focusing on compliance with stringent regulatory standards. As pharmaceutical demand continues to rise worldwide, the Global Microbial API Market is projected to grow steadily.
Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:
Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.
Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.
Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.
Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.
Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.
Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.
Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.
MARKET SEGMENTATION
By Host
- Mammalian
- Bacterial
- Fungal
By Type
- Antibody
- Peptide
- Protein
- Small Molecule
- Vaccine
By Site
- In-house
- Outsourced
By End User
- Pharmaceutical Companies
- Biopharmaceutical Companies
- Others
COMPANIES PROFILED
- Merck Co Inc, Topfond Pharmaceutical Co Ltd, DSM, CSPC Pharmaceutical Group Limited, KOLON LIFE SCIENCE, Teva Pharmaceutical Industries Ltd, Lonza, Akums Lifesciences Ltd, AbbVie Inc, Xellia Pharmaceuticals, BASF, Dr Reddys Laboratories and Lupin
- We can customise the report as per your requirements.
TABLE OF CONTENTS
Chapter 1. PREFACE
- 1.1. Market Segmentation & Scope
- 1.2. Market Definition
- 1.3. Information Procurement
- 1.3.1 Information Analysis
- 1.3.2 Market Formulation & Data Visualization
- 1.3.3 Data Validation & Publishing
- 1.4. Research Scope and Assumptions
- 1.4.1 List of Data Sources
Chapter 2. EXECUTIVE SUMMARY
- 2.1. Market Snapshot
- 2.2. Segmental Outlook
- 2.3. Competitive Outlook
Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK
- 3.1. Market Lineage Outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Value Chain Analysis
- 3.4. Regulatory Framework
- 3.4.1 Standards & Compliance
- 3.4.2 Regulatory Impact Analysis
- 3.5. Market Dynamics
- 3.5.1 Market Drivers
- 3.5.2 Market Restraints
- 3.5.3 Market Opportunities
- 3.5.4 Market Challenges
- 3.6. Porter's Five Forces Analysis
- 3.7. PESTLE Analysis
Chapter 4. GLOBAL MICROBIAL API MARKET: BY HOST 2022-2034 (USD MN)
- 4.1. Market Analysis, Insights and Forecast Host
- 4.2. Mammalian Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 4.3. Bacterial Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 4.4. Fungal Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 5. GLOBAL MICROBIAL API MARKET: BY TYPE 2022-2034 (USD MN)
- 5.1. Market Analysis, Insights and Forecast Type
- 5.2. Antibody Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 5.3. Peptide Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 5.4. Protein Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 5.5. Small Molecule Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 5.6. Vaccine Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 6. GLOBAL MICROBIAL API MARKET: BY SITE 2022-2034 (USD MN)
- 6.1. Market Analysis, Insights and Forecast Site
- 6.2. In-house Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.3. Outsourced Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 7. GLOBAL MICROBIAL API MARKET: BY END USER 2022-2034 (USD MN)
- 7.1. Market Analysis, Insights and Forecast End User
- 7.2. Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 7.3. Biopharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 7.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 8. GLOBAL MICROBIAL API MARKET: BY REGION 2022-2034(USD MN)
- 8.1. Regional Outlook
- 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.2.1 By Host
- 8.2.2 By Type
- 8.2.3 By Site
- 8.2.4 By End User
- 8.2.5 United States
- 8.2.6 Canada
- 8.2.7 Mexico
- 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.3.1 By Host
- 8.3.2 By Type
- 8.3.3 By Site
- 8.3.4 By End User
- 8.3.5 United Kingdom
- 8.3.6 France
- 8.3.7 Germany
- 8.3.8 Italy
- 8.3.9 Russia
- 8.3.10 Rest Of Europe
- 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.4.1 By Host
- 8.4.2 By Type
- 8.4.3 By Site
- 8.4.4 By End User
- 8.4.5 India
- 8.4.6 Japan
- 8.4.7 South Korea
- 8.4.8 Australia
- 8.4.9 South East Asia
- 8.4.10 Rest Of Asia Pacific
- 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.5.1 By Host
- 8.5.2 By Type
- 8.5.3 By Site
- 8.5.4 By End User
- 8.5.5 Brazil
- 8.5.6 Argentina
- 8.5.7 Peru
- 8.5.8 Chile
- 8.5.9 South East Asia
- 8.5.10 Rest of Latin America
- 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.6.1 By Host
- 8.6.2 By Type
- 8.6.3 By Site
- 8.6.4 By End User
- 8.6.5 Saudi Arabia
- 8.6.6 UAE
- 8.6.7 Israel
- 8.6.8 South Africa
- 8.6.9 Rest of the Middle East And Africa
Chapter 9. COMPETITIVE LANDSCAPE
- 9.1. Recent Developments
- 9.2. Company Categorization
- 9.3. Supply Chain & Channel Partners (based on availability)
- 9.4. Market Share & Positioning Analysis (based on availability)
- 9.5. Vendor Landscape (based on availability)
- 9.6. Strategy Mapping
Chapter 10. COMPANY PROFILES OF GLOBAL MICROBIAL API INDUSTRY
- 10.1. Top Companies Market Share Analysis
- 10.2. Company Profiles
- 10.2.1 Merck & Co. Inc
- 10.2.2 Topfond Pharmaceutical Co. Ltd
- 10.2.3 DSM
- 10.2.4 CSPC Pharmaceutical Group Limited
- 10.2.5 KOLON LIFE SCIENCE
- 10.2.6 Teva Pharmaceutical Industries Ltd
- 10.2.7 Lonza
- 10.2.8 Akums Lifesciences Ltd
- 10.2.9 AbbVie Inc
- 10.2.10 Xellia Pharmaceuticals
- 10.2.11 BASF
- 10.2.12 Dr. Reddy'S Laboratories And Lupin
